$38.50
+4.05%Oct 13, 2026, 10:22 UTC
GENMAB A/S announced that worldwide third-quarter 2026 net trade sales of DARZALEX, as reported by JOHNSON & JOHNSON, were USD 4,239 million, including USD 2,528 million in the United States and USD 1,711 million in the rest of the world.
Source:Oct 6, 2026, 09:51 UTC
Genmab (GMAB) shares jumped 10.7% in the previous trading session on above-average trading volume.
Source:Oct 6, 2026, 08:35 UTC
Genmab reported positive study results showing its Epkinly drug extended survival time for patients with a common type of lymphoma.
Source:Oct 5, 2026, 18:49 UTC
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial showing epcoritamab in combination with R-CHOP achieved statistically significant improvement in progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients, and will engage global regulatory authorities.
Oct 5, 2026, 14:00 UTC
Genmab shares continued to rise in Copenhagen, gaining as much as 6%.
Source:Oct 3, 2026, 19:40 UTC
Genmab A/S announced Phase 2 RAINFOL-01 Part C results showing rinatabart sesutecan (Rina-S) achieved a 45.9% confirmed objective response rate and 12.1-month median duration of response in 109 patients with platinum-resistant ovarian cancer, presented at the IGCS Congress 2026 in Montreal, Canada.
Source:Sep 24, 2026, 18:32 UTC
Genmab A/S granted 13,794 restricted stock units and 13,331 warrants to employees of the company and its subsidiaries.
Source:Sep 8, 2026, 18:44 UTC
Genmab A/S increased its share capital by 28,011 shares due to the exercise of employee warrants, without preemption rights for existing shareholders.
Source:Aug 6, 2026, 18:04 UTC
Genmab announced two new Phase III studies of petosemtamab in colorectal cancer.
Source:Jun 30, 2026, 09:35 UTC
Genmab and AbbVie announced that their drug combination for lymphoma met the primary goal in a late-stage clinical trial.